3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
150
Lung Neoplasms
58
Pancreatic Neoplasms
34
Neoplasms
20
Neoplasm Metastasis
15
Breast Neoplasms
15
Adenocarcinoma of Lung
15
Brain Neoplasms
14
Adenocarcinoma, Bronchiolo-Alveolar
13
Glioblastoma
12
Non-Squamous Non-Small Cell Lung Cancer
11
Head and Neck Neoplasms
11
Gliosarcoma
11
Squamous Cell Carcinoma of Head and Neck
10
Carcinoma, Hepatocellular
10
Colorectal Neoplasms
8
Carcinoma, Renal Cell
8
Esophageal Neoplasms
6
Urinary Bladder Neoplasms
5
Gallbladder Neoplasms
5
Colonic Neoplasms
5
Central Nervous System Neoplasms
5
Carcinoma, Squamous Cell
5
Adenocarcinoma
5
Rectal Neoplasms
4
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Liver Neoplasms
4
Kidney Neoplasms
4
Fallopian Tube Neoplasms
4
Interventions
Gefitinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Advanced Stage Non Small Cell Lung Cancer
×
Erlotinib Hydrochloride
×
Clear all
NCT01955421
2015-07-03
NSCLC EGFR TKI
Sun Yat-sen University
Phase 2
Unknown
224 enrolled